Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
26
NVNO Quote, Financials, Valuation and Earnings
Last price:
$2.52
Seasonality move
:
0.78%
Day range:
$2.45 - $2.74
52-week range:
$2.45 - $6.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
213.30x
P/B ratio:
0.93x
Volume:
691.8K
Avg. volume:
151.2K
1-year change:
-45.27%
Market cap:
$43.9M
Revenue:
--
EPS (TTM):
-$1.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVNO
enVVeno Medical
|
-- | -$0.33 | -- | -26.67% | -- |
|
CVRX
CVRx
|
$13.2M | -$0.47 | 34.46% | -11.77% | -- |
|
NMTC
NeuroOne Medical Technologies
|
-- | -- | 157.41% | -57.14% | -- |
|
NTRB
Nutriband
|
-- | -- | -- | -- | -- |
|
SINT
SINTX Technologies
|
$700K | -$5.29 | 20.07% | -96.58% | -- |
|
XAIR
Beyond Air
|
$1M | -- | 138.36% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVNO
enVVeno Medical
|
$2.50 | -- | $43.9M | -- | $0.00 | 0% | 213.30x |
|
CVRX
CVRx
|
$12.11 | -- | $293.8M | -- | $0.00 | 0% | 5.54x |
|
NMTC
NeuroOne Medical Technologies
|
$0.76 | -- | $23.4M | -- | $0.00 | 0% | 5.88x |
|
NTRB
Nutriband
|
$4.05 | -- | $45M | -- | $0.00 | 0% | 19.85x |
|
SINT
SINTX Technologies
|
$3.52 | -- | $4.7M | -- | $0.00 | 0% | 0.96x |
|
XAIR
Beyond Air
|
$0.41 | -- | $29.6M | -- | $0.00 | 0% | 7.10x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVNO
enVVeno Medical
|
-- | 2.437 | -- | -- |
|
CVRX
CVRx
|
43.02% | 0.327 | 23.08% | 9.97x |
|
NMTC
NeuroOne Medical Technologies
|
-- | -1.235 | -- | 0.74x |
|
NTRB
Nutriband
|
1.68% | 2.279 | 0.28% | 4.65x |
|
SINT
SINTX Technologies
|
2.35% | 0.698 | 3.06% | 2.48x |
|
XAIR
Beyond Air
|
28.48% | 1.673 | 38.38% | 4.46x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVNO
enVVeno Medical
|
-- | -$6.2M | -- | -- | -- | -$4.3M |
|
CVRX
CVRx
|
$11.1M | -$13M | -58.86% | -84.64% | -90.44% | -$10.4M |
|
NMTC
NeuroOne Medical Technologies
|
$141.1K | -$2.8M | -335.54% | -335.54% | -1108.64% | -$2.7M |
|
NTRB
Nutriband
|
$191K | -$1.4M | -65.19% | -69.58% | -210.38% | -$1.1M |
|
SINT
SINTX Technologies
|
$157K | -$2M | -130.78% | -132.95% | -1697.55% | -$2.6M |
|
XAIR
Beyond Air
|
-$1.1M | -$12.8M | -140.46% | -219.34% | -1641.86% | -$14.5M |
enVVeno Medical vs. Competitors
-
Which has Higher Returns NVNO or CVRX?
CVRx has a net margin of -- compared to enVVeno Medical's net margin of -97.95%. enVVeno Medical's return on equity of -- beat CVRx's return on equity of -84.64%.
Company Gross Margin Earnings Per Share Invested Capital NVNOenVVeno Medical-- -$0.35 -- CVRXCVRx83.19% -$0.57 $114.4M -
What do Analysts Say About NVNO or CVRX?
enVVeno Medical has a consensus price target of --, signalling upside risk potential of 619.71%. On the other hand CVRx has an analysts' consensus of -- which suggests that it could grow by 50.01%. Given that enVVeno Medical has higher upside potential than CVRx, analysts believe enVVeno Medical is more attractive than CVRx.
Company Buy Ratings Hold Ratings Sell Ratings NVNOenVVeno Medical0 0 0 CVRXCVRx0 0 0 -
Is NVNO or CVRX More Risky?
enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison CVRx has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NVNO or CVRX?
enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CVRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. CVRx pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVNO or CVRX?
enVVeno Medical quarterly revenues are --, which are smaller than CVRx quarterly revenues of $13.4M. enVVeno Medical's net income of -$5.6M is higher than CVRx's net income of -$13.1M. Notably, enVVeno Medical's price-to-earnings ratio is -- while CVRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 213.30x versus 5.54x for CVRx. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVNOenVVeno Medical213.30x -- -- -$5.6M CVRXCVRx5.54x -- $13.4M -$13.1M
-
Which has Higher Returns NVNO or NMTC?
NeuroOne Medical Technologies has a net margin of -- compared to enVVeno Medical's net margin of -1230.55%. enVVeno Medical's return on equity of -- beat NeuroOne Medical Technologies's return on equity of -335.54%.
Company Gross Margin Earnings Per Share Invested Capital NVNOenVVeno Medical-- -$0.35 -- NMTCNeuroOne Medical Technologies51.81% -$0.11 $822K -
What do Analysts Say About NVNO or NMTC?
enVVeno Medical has a consensus price target of --, signalling upside risk potential of 619.71%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 163.78%. Given that enVVeno Medical has higher upside potential than NeuroOne Medical Technologies, analysts believe enVVeno Medical is more attractive than NeuroOne Medical Technologies.
Company Buy Ratings Hold Ratings Sell Ratings NVNOenVVeno Medical0 0 0 NMTCNeuroOne Medical Technologies0 0 0 -
Is NVNO or NMTC More Risky?
enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.224%.
-
Which is a Better Dividend Stock NVNO or NMTC?
enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVNO or NMTC?
enVVeno Medical quarterly revenues are --, which are smaller than NeuroOne Medical Technologies quarterly revenues of $272.3K. enVVeno Medical's net income of -$5.6M is lower than NeuroOne Medical Technologies's net income of -$3.4M. Notably, enVVeno Medical's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 213.30x versus 5.88x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVNOenVVeno Medical213.30x -- -- -$5.6M NMTCNeuroOne Medical Technologies5.88x -- $272.3K -$3.4M
-
Which has Higher Returns NVNO or NTRB?
Nutriband has a net margin of -- compared to enVVeno Medical's net margin of -211%. enVVeno Medical's return on equity of -- beat Nutriband's return on equity of -69.58%.
Company Gross Margin Earnings Per Share Invested Capital NVNOenVVeno Medical-- -$0.35 -- NTRBNutriband29.58% -$0.12 $11.4M -
What do Analysts Say About NVNO or NTRB?
enVVeno Medical has a consensus price target of --, signalling upside risk potential of 619.71%. On the other hand Nutriband has an analysts' consensus of -- which suggests that it could grow by 344.44%. Given that enVVeno Medical has higher upside potential than Nutriband, analysts believe enVVeno Medical is more attractive than Nutriband.
Company Buy Ratings Hold Ratings Sell Ratings NVNOenVVeno Medical0 0 0 NTRBNutriband0 0 0 -
Is NVNO or NTRB More Risky?
enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison Nutriband has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.193%.
-
Which is a Better Dividend Stock NVNO or NTRB?
enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVNO or NTRB?
enVVeno Medical quarterly revenues are --, which are smaller than Nutriband quarterly revenues of $645.8K. enVVeno Medical's net income of -$5.6M is lower than Nutriband's net income of -$1.4M. Notably, enVVeno Medical's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 213.30x versus 19.85x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVNOenVVeno Medical213.30x -- -- -$5.6M NTRBNutriband19.85x -- $645.8K -$1.4M
-
Which has Higher Returns NVNO or SINT?
SINTX Technologies has a net margin of -- compared to enVVeno Medical's net margin of -1700%. enVVeno Medical's return on equity of -- beat SINTX Technologies's return on equity of -132.95%.
Company Gross Margin Earnings Per Share Invested Capital NVNOenVVeno Medical-- -$0.35 -- SINTSINTX Technologies42.78% -$6.96 $5.7M -
What do Analysts Say About NVNO or SINT?
enVVeno Medical has a consensus price target of --, signalling upside risk potential of 619.71%. On the other hand SINTX Technologies has an analysts' consensus of -- which suggests that it could grow by 1888.64%. Given that SINTX Technologies has higher upside potential than enVVeno Medical, analysts believe SINTX Technologies is more attractive than enVVeno Medical.
Company Buy Ratings Hold Ratings Sell Ratings NVNOenVVeno Medical0 0 0 SINTSINTX Technologies0 0 0 -
Is NVNO or SINT More Risky?
enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.497, suggesting its more volatile than the S&P 500 by 49.673%.
-
Which is a Better Dividend Stock NVNO or SINT?
enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVNO or SINT?
enVVeno Medical quarterly revenues are --, which are smaller than SINTX Technologies quarterly revenues of $367K. enVVeno Medical's net income of -$5.6M is higher than SINTX Technologies's net income of -$6.2M. Notably, enVVeno Medical's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 213.30x versus 0.96x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVNOenVVeno Medical213.30x -- -- -$5.6M SINTSINTX Technologies0.96x -- $367K -$6.2M
-
Which has Higher Returns NVNO or XAIR?
Beyond Air has a net margin of -- compared to enVVeno Medical's net margin of -1673.94%. enVVeno Medical's return on equity of -- beat Beyond Air's return on equity of -219.34%.
Company Gross Margin Earnings Per Share Invested Capital NVNOenVVeno Medical-- -$0.35 -- XAIRBeyond Air-135.84% -$0.28 $40.5M -
What do Analysts Say About NVNO or XAIR?
enVVeno Medical has a consensus price target of --, signalling upside risk potential of 619.71%. On the other hand Beyond Air has an analysts' consensus of -- which suggests that it could grow by 510.5%. Given that enVVeno Medical has higher upside potential than Beyond Air, analysts believe enVVeno Medical is more attractive than Beyond Air.
Company Buy Ratings Hold Ratings Sell Ratings NVNOenVVeno Medical0 0 0 XAIRBeyond Air0 0 0 -
Is NVNO or XAIR More Risky?
enVVeno Medical has a beta of 1.219, which suggesting that the stock is 21.904% more volatile than S&P 500. In comparison Beyond Air has a beta of -0.225, suggesting its less volatile than the S&P 500 by 122.529%.
-
Which is a Better Dividend Stock NVNO or XAIR?
enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beyond Air offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. Beyond Air pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVNO or XAIR?
enVVeno Medical quarterly revenues are --, which are smaller than Beyond Air quarterly revenues of $798K. enVVeno Medical's net income of -$5.6M is higher than Beyond Air's net income of -$13.4M. Notably, enVVeno Medical's price-to-earnings ratio is -- while Beyond Air's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 213.30x versus 7.10x for Beyond Air. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVNOenVVeno Medical213.30x -- -- -$5.6M XAIRBeyond Air7.10x -- $798K -$13.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
